Comparative Pharmacology
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus PARADIONE.
OXCARBAZEPINE EXTENDED RELEASE TABLETS vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, inhibiting repetitive firing of action potentials, and reducing the propagation of synaptic impulses. Also modulates calcium channels and enhances potassium conductance.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Initial: 300 mg orally twice daily. Increase by up to 600 mg/day at weekly intervals. Target maintenance: 1200-2400 mg/day in two divided doses. Extended-release tablets are dosed once daily: initial 600 mg, titrate weekly by 600 mg to maintenance 1200-2400 mg once daily.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
Oxcarbazepine: ~2 hours (not clinically relevant due to rapid conversion to MHD). MHD: ~9 hours (steady-state achieved in 2-3 days).
12-24 hours (terminal); prolonged in renal impairment
Renal: ~70% (mainly as glucuronide conjugates of MHD and oxcarbazepine, with <1% unchanged oxcarbazepine and ~27% unchanged MHD). Fecal: <1%.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant